- Details
- Sam Chang and Karan Jatwani discuss the role of adjuvant chemotherapy, versus observation, in patients with upper urinary tracts with variant histology undergoing a radical nephroureterectomy. The study, which analyzed data from the National Cancer Database from 2004 to 2018, found no difference in overall survival between patients who received chemotherapy and those who did not. The study focused...
|
- Details
- Alexander Laird joins Sam Chang in conversation to discuss data aimed at identifying clinical and radiological factors that could predict upper tract urothelial carcinoma to avoid diagnostic ureteroscopy in selected patients. The study found that patients with a final diagnosis of upper tract urothelial carcinoma tended to be older, smokers, had a history of previous abdominal surgery, presented w...
|
- Details
- Min Yuen Teo joins Sam Chang in a discussion on an ongoing Phase II clinical trial on neoadjuvant immune checkpoint inhibition, with both a combination of nivolumab and ipilimumab in patients with high grade invasive upper tract urothelial cancer who are cisplatin-ineligible. It was designed as a Phase II study with a two stage design. The study's primary endpoint was pathologic complete response;...
|
- Details
- Wesley Yip and Jonathan Coleman join Sam Chang in a conversation discussing the impact of neoadjuvant chemotherapy prior to radical nephroureterectomy and its possible benefit on patients with high-grade upper tract urothelial carcinoma. Upper tract urothelial carcinoma is rare but deadly, with 5-year cancer-specific mortality rates of 21-59%. High-grade disease defines a high-risk population, and...
|
- Details
- Daniel Joyce joins Sam Chang to discuss oncologic outcomes, costs, and quality metrics for patients with both synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC). Upper tract urothelial carcinoma accounts for around 10% of all urothelial cancer cases that appear. Just around half of those will develop metastatic illness. This work's main objective was to determine what...
|
- Details
- Marco Moschini joins Sam Chang in a discussion on highlighting a European Urology Oncology publication that sought to review the available literature systematically focused on incidence, diagnosis, clinicopathological features, oncological outcomes, and screening protocols for upper tract urothelial carcinoma (UTUC) among Lynch syndrome patients. This study aims to reduce misdiagnosis and improve...
|
- Details
- Sam Chang and Paolo Gontero discuss the updated EAU guidelines for upper tract urothelial carcinoma (UTUC), focusing on three main topics that have been subject to revision. Drs. Gontero and Chang discuss the relationship between UTUC and genetics and the recommendation that patients presented with UTUC should receive a medical history that is focused on ruling out Lynch syndrome prompting germlin...
|
- Details
- Sam Chang is joined by Katherine Fero and Stephen Williams to discuss their work evaluating the treatment patterns, costs, and survival outcomes among patients with nonmetastatic upper tract urothelial carcinoma (UTUC) in the United States. This research sought to look at and see how contemporarily patients are being managed with a real-world study sample looking at treatment patterns and then the...
|
- Details
- Sam Chang and Woodson "Woody" Smelser explore an innovative trial for upper tract urothelial carcinoma (UTUC). Dr. Smelser, previously mentored by Dr. Chang, has initiated this pioneering trial which aims to employ pembrolizumab, an immunotherapy drug, for patients with high-risk UTUC who are unfit or unwilling to undergo radical nephroureterectomy. The multi-site trial will utilize maximum endosc...
|
- Details
- Sam Chang hosts Jean Hoffman-Censits who introduces an innovative clinical trial, ECOG-ACRIN 8192, which focuses on preoperative treatment for patients with high-grade upper tract urothelial cancer. The trial, which she helps lead, seeks to administer neoadjuvant chemotherapy, potentially improving patient outcomes. The therapy's success in muscle-invasive bladder cancer serves as a foundation for...
|
